PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS - Related Studies

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

This study is ongoing, but not recruiting participants.

Study NCT00439673. Last updated on November 7, 2008. Information provided by Gruppo Italiano Malattie EMatologiche dell'Adulto

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Myelodysplastic Syndromes

2	Additional conditions recognized in this trial
		Preleukemia
		Syndrome

3	More general conditions related to this trial
		Bone Marrow Diseases
		Disease
		Hematologic Diseases
		Neoplasms
		Pathologic Processes
		Precancerous Conditions

4	Interventions listed in this trial
		5-Azacytidine
		Valproic Acid
		ATRA

5	Additional drug interventions recognized in this trial
		Azacitidine

6	More general drug interventions related to this trial
		Anticonvulsants
		Antimanic Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Central Nervous System Agents
		Central Nervous System Depressants
		Enzyme Inhibitors
		GABA Agents
		Molecular Mechanisms of Pharmacological Action
		Neurotransmitter Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Psychotropic Drugs
		Therapeutic Uses
		Tranquilizing Agents

7	Sponsors listed in this trial
		Gruppo Italiano Malattie EMatologiche dell'Adulto